Epigenetic actions of environmental factors and promising drugs for cancer therapy (Review)
- Authors:
- Zhong‑Tian Bai
- Bing Bai
- Jun Zhu
- Cui‑Xia Di
- Xun Li
- Wen‑Ce Zhou
-
Affiliations: The Second Department of General Surgery, Key Laboratory of Biotherapy and Regenerative Medicine, First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Pathology Department of Donggang Branch Courts, First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Department of Heavy Ion Radiation Medicine, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000, P.R. China - Published online on: December 13, 2017 https://doi.org/10.3892/ol.2017.7597
- Pages: 2049-2056
This article is mentioned in:
Abstract
Skinner MK, Manikkam M and Guerrero-Bosagna C: Epigenetic transgenerational actions of environmental factors in disease etiology. Trends Endocrinol Metab. 21:214–222. 2010. View Article : Google Scholar : PubMed/NCBI | |
Lopez-Ramirez MA and Nicoli S: Role of miRNAs and epigenetics in neural stem cell fate determination. Epigenetics. 9:90–100. 2014. View Article : Google Scholar : PubMed/NCBI | |
Graça I, Pereira-Silva E, Henrique R, Packham G, Crabb SJ and Jerónimo C: Epigenetic modulators as therapeutic targets in prostate cancer. Clin Epigenetics. 8:982016. View Article : Google Scholar : PubMed/NCBI | |
Do C, Shearer A, Suzuki M, Terry MB, Gelernter J, Greally JM and Tycko B: Genetic-epigenetic interactions in cis: A major focus in the post-GWAS era. Genome Biol. 18:1202017. View Article : Google Scholar : PubMed/NCBI | |
Shukla SD and Lim RW: Epigenetic effects of ethanol on the liver and gastrointestinal system. Alcohol Res. 35:47–55. 2013.PubMed/NCBI | |
Rothbart SB and Strahl BD: Interpreting the language of histone and DNA modifications. Biochim Biophys Acta. 1839:627–643. 2014. View Article : Google Scholar : PubMed/NCBI | |
Wilkins BJ, Rall NA, Ostwal Y, Kruitwagen T, Hiragami-Hamada K, Winkler M, Barral Y, Fischle W and Neumann H: A cascade of histone modifications induces chromatin condensation in mitosis. Science. 343:77–80. 2014. View Article : Google Scholar : PubMed/NCBI | |
Tracey R, Manikkam M, Guerrero-Bosagna C and Skinner MK: Hydrocarbons (jet fuel JP-8) induce epigenetic transgenerational inheritance of obesity, reproductive disease and sperm epimutations. Reprod Toxicol. 36:104–116. 2013. View Article : Google Scholar : PubMed/NCBI | |
Heijmans BT, Tobi EW, Stein AD, Putter H, Blauw GJ, Susser ES, Slagboom PE and Lumey LH: Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci USA. 105:17046–17049. 2008. View Article : Google Scholar : PubMed/NCBI | |
Perera F, Tang WY, Herbstman J, Tang D, Levin L, Miller R and Ho SM: Relation of DNA methylation of 5′-CpG island of ACSL3 to transplacental exposure to airborne polycyclic aromatic hydrocarbons and childhood asthma. PLoS One. 4:e44882009. View Article : Google Scholar : PubMed/NCBI | |
Novikova SI, He F, Bai J, Cutrufello NJ, Lidow MS and Undieh AS: Maternal cocaine administration in mice alters DNA methylation and gene expression in hippocampal neurons of neonatal and prepubertal offspring. PLoS One. 3:e19192008. View Article : Google Scholar : PubMed/NCBI | |
Jiménez-Chillarón JC, Nijland MJ, Ascensão AA, Sardão VA, Magalhães J, Hitchler MJ, Domann FE and Oliveira PJ: Back to the future: Transgenerational transmission of xenobiotic-induced epigenetic remodeling. Epigenetics. 10:259–273. 2015. View Article : Google Scholar : PubMed/NCBI | |
Zhang Y: Detection of epigenetic aberrations in the development of hepatocellular carcinoma. Methods Mol Biol. 1238:709–731. 2015. View Article : Google Scholar : PubMed/NCBI | |
Tian Y, Yang W, Song J, Wu Y and Ni B: Hepatitis B virus X protein-induced aberrant epigenetic modifications contributing to human hepatocellular carcinoma pathogenesis. Mol Cell Biol. 33:2810–2816. 2013. View Article : Google Scholar : PubMed/NCBI | |
Ryu HW, Lee DH, Won HR, Kim KH, Seong YJ and Kwon SH: Influence of toxicologically relevant metals on human epigenetic regulation. Toxicol Res. 31:1–9. 2015. View Article : Google Scholar : PubMed/NCBI | |
Khan D and Ahmed SA: Epigenetic regulation of non-lymphoid cells by Bisphenol A, a model endocrine disrupter: Potential implications for immunoregulation. Front Endocrinol (Lausanne). 6:912015.PubMed/NCBI | |
Guerrero-Bosagna C and Skinner MK: Environmentally induced epigenetic transgenerational inheritance of phenotype and disease. Mol Cell Endocrinol. 354:3–8. 2012. View Article : Google Scholar : PubMed/NCBI | |
Godfrey KM, Costello PM and Lillycrop KA: The developmental environment, epigenetic biomarkers and long-term health. J Dev Orig Health Dis. 6:399–406. 2015. View Article : Google Scholar : PubMed/NCBI | |
Jirtle RL and Skinner MK: Environmental epigenomics and disease susceptibility. Nat Rev Genet. 8:253–262. 2007. View Article : Google Scholar : PubMed/NCBI | |
Dippold RP, Vadigepalli R, Gonye GE, Patra B and Hoek JB: Chronic ethanol feeding alters miRNA expression dymanics during liver regeneration. Alcohol Clin Exp Res. 37:E59–E69. 2013. View Article : Google Scholar : PubMed/NCBI | |
Pogribny IP and Rusyn I: Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett. 342:223–230. 2014. View Article : Google Scholar : PubMed/NCBI | |
Wei X, Xiang T, Ren G, Tan C, Liu R, Xu X and Wu Z: miR-101 is down-regulated by the hepatitis B virus X protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. Cell Signal. 25:439–446. 2013. View Article : Google Scholar : PubMed/NCBI | |
Dhanak D and Jackson P: Development and classes of epigenetic drugs for cancer. Biochem Biophys Res Commun. 455:58–69. 2014. View Article : Google Scholar : PubMed/NCBI | |
Wang Z and Patel DJ: Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases. Q Rev Biophys. 46:349–373. 2013. View Article : Google Scholar : PubMed/NCBI | |
Enjuanes A, Albero R, Clot G, Navarro A, Beà S, Pinyol M, Martín-Subero JI, Klapper W, Staudt LM, Jaffe ES, et al: Genomewide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. Int J Cancer. 133:2852–2863. 2013.PubMed/NCBI | |
Müller AM and Florek M: 5-Azacytidine/5-Azacitidine. Recent Results Cancer Res. 201:299–324. 2014. View Article : Google Scholar : PubMed/NCBI | |
Momparler RL: Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine). Semin Oncol. 32:443–451. 2005. View Article : Google Scholar : PubMed/NCBI | |
Zhao Q, Fan J, Hong W, Li L and Wu M: Inhibition of cancer cell proliferation by 5-fluoro-2′-deoxycytidine, a DNA methylation inhibitor, through activation of DNA damage response pathway. Springerplus. 1:652012. View Article : Google Scholar : PubMed/NCBI | |
Marquez VE, Kelley JA, Agbaria R, Ben-Kasus T, Cheng JC, Yoo CB and Jones PA: Zebularine: A unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann N Y Acad Sci. 1058:246–254. 2005. View Article : Google Scholar : PubMed/NCBI | |
Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Taverna P, Karpf AR and Griffiths EA: Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 10:237–246. 2015. View Article : Google Scholar : PubMed/NCBI | |
Agarwal S, Amin KS, Jagadeesh S, Baishay G, Rao PG, Barua NC, Bhattacharya S and Banerjee PP: Mahanine restores RASSF1A expression by down-regulating DNMT1 and DNMT3B in prostate cancer cells. Mol Cancer. 12:992013. View Article : Google Scholar : PubMed/NCBI | |
Dueñas-Gonzalez A, Coronel J, Cetina L, González-Fierro A, Chavez-Blanco A and Taja-Chayeb L: Hydralazine-valproate: A repositioned drug combination for the epigenetic therapy of cancer. Expert Opin Drug Metab Toxicol. 10:1433–1444. 2014. View Article : Google Scholar : PubMed/NCBI | |
Gao Z, Xu Z, Hung MS, Lin YC, Wang T, Gong M, Zhi X, Jablons DM and You L: Procaine and procainamide inhibit the Wnt canonical pathway by promoter demethylation of WIF-1 in lung cancer cells. Oncol Rep. 22:1479–1484. 2009.PubMed/NCBI | |
Rilova E, Erdmann A, Gros C, Masson V, Aussagues Y, Poughon-Cassabois V, Rajavelu A, Jeltsch A, Menon Y, Novosad N, et al: Design, synthesis and biological evaluation of 4-amino-N-(4-aminophenyl) benzamide analogues of quinoline-based SGI-1027 as inhibitors of DNA methylation. ChemMedChem. 9:590–601. 2014. View Article : Google Scholar : PubMed/NCBI | |
Ramasamy TS, Ayob AZ, Myint HH, Thiagarajah S and Amini F: Targeting colorectal cancer stem cells using curcumin and curcumin analogues: Insights into the mechanism of the therapeutic efficacy. Cancer Cell Int. 15:962015. View Article : Google Scholar : PubMed/NCBI | |
Graça I, Sousa EJ, Baptista T, Almeida M, Ramalho-Carvalho J, Palmeira C, Henrique R and Jerónimo C: Anti-tumoral effect of the non-nucleoside DNMT inhibitor RG108 in human prostate cancer cells. Curr Pharm Des. 20:1803–1811. 2014. View Article : Google Scholar : PubMed/NCBI | |
Lee E, Jeong KW, Jnawali HN, Shin A, Heo YS and Kim Y: Cytotoxic activity of 3,6-dihydroxyflavone in human cervical cancer cells and its therapeutic effect on c-Jun N-terminal kinase inhibition. Molecules. 19:13200–13211. 2014. View Article : Google Scholar : PubMed/NCBI | |
Chakrabarty S, Ganguli A, Das A, Nag D and Chakrabarti G: Epigallocatechin-3-gallate shows anti-proliferative activity in HeLa Cells targeting tubulin-microtubule equilibrium. Chem Biol Interact. 242:380–389. 2015. View Article : Google Scholar : PubMed/NCBI | |
Shukla S and Gupta S: Apigenin: A promising molecule for cancer prevention. Pharm Res. 27:962–978. 2010. View Article : Google Scholar : PubMed/NCBI | |
Qiang W, Jin T, Yang Q, Liu W, Liu S, Ji M, He N, Chen C, Shi B and Hou P: PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells. J Biomed Nanotechnol. 10:1249–1258. 2014. View Article : Google Scholar : PubMed/NCBI | |
Spagnuolo C, Russo GL, Orhan IE, Habtemariam S, Daglia M, Sureda A, Nabavi SF, Devi KP, Loizzo MR, Tundis R and Nabavi SM: Genistein and cancer: Current status, challenges, and future directions. Adv Nutr. 6:408–419. 2015. View Article : Google Scholar : PubMed/NCBI | |
Wyrębska A, Gach K and Janecka A: Combined effect of parthenolide and various anti-cancer drugs or anticancer candidate substances on malignant cells in vitro and in vivo. Mini Rev Med Chem. 14:222–228. 2014. View Article : Google Scholar : PubMed/NCBI | |
Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, Cirstea D, Hu Y, Mimura N, Ohguchi H, Cottini F, et al: Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia. 28:680–689. 2014. View Article : Google Scholar : PubMed/NCBI | |
Richon VM: Targeting histone deacetylases: Development of vorinostat for the treatment of cancer. Epigenomics. 2:457–465. 2010. View Article : Google Scholar : PubMed/NCBI | |
Li X, Zhang J, Xie Y, Jiang Y, Yingjie Z and Xu W: Progress of HDAC inhibitor panobinostat in the treatment of cancer. Curr Drug Targets. 15:622–634. 2014. View Article : Google Scholar : PubMed/NCBI | |
Wang X, Xu J, Wang H, Wu L, Yuan W, Du J and Cai S: Trichostatin A, a histone deacetylase inhibitor, reverses epithelial-mesenchymal transition in colorectal cancer SW480 and prostate cancer PC3 cells. Biochem Biophys Res Commun. 456:320–326. 2015. View Article : Google Scholar : PubMed/NCBI | |
Ganai SA: Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: The novel paradigm to tackle monotonous cancer chemoresistance. Arch Pharm Res. 2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
Xing LF, Wang DT, Yang Y and Pan SY: Effect of HDAC-6 on PD cell induced by lactacystin. Asian Pac J Trop Med. 8:855–859. 2015. View Article : Google Scholar : PubMed/NCBI | |
Kirschbaum MH, Foon KA, Frankel P, Ruel C, Pulone B, Tuscano JM and Newman EM: A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: A California Cancer Consortium study. Leuk Lymphoma. 55:2301–2304. 2014. View Article : Google Scholar : PubMed/NCBI | |
Bertino EM and Otterson GA: Romidepsin: A novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs. 20:1151–1158. 2011. View Article : Google Scholar : PubMed/NCBI | |
Ruiz R, Raez LE and Rolfo C: Entinostat (SNDX-275) for the treatment of non-small cell lung cancer. Expert Opin Investig Drugs. 24:1101–1109. 2015. View Article : Google Scholar : PubMed/NCBI | |
Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E and Herrera LA: Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev. 34:206–222. 2008. View Article : Google Scholar : PubMed/NCBI | |
Tsunedomi R, Iizuka N, Harada S and Oka M: Susceptibility of hepatoma-derived cells to histone deacetylase inhibitors is associated with ID2 expression. Int J Oncol. 42:1159–1166. 2013. View Article : Google Scholar : PubMed/NCBI | |
Nielsen TK, Hildmann C, Riester D, Wegener D, Schwienhorst A and Ficner R: Complex structure of a bacterial class 2 histone deacetylase homologue with a trifluoromethylketone inhibitor. Acta Crystallogr Sect F Struct Biol Cryst Commun. 63:270–273. 2007. View Article : Google Scholar : PubMed/NCBI | |
Tao YF, Lin F, Yan XY, Gao XG, Teng F, Fu ZR and Wang ZX: Galectin-9 in combination with EX-527 prolongs the survival of cardiac allografts in mice after cardiac transplantation. Transplant Proc. 47:2003–2009. 2015. View Article : Google Scholar : PubMed/NCBI | |
Mahajan SS, Scian M, Sripathy S, Posakony J, Lao U, Loe TK, Leko V, Thalhofer A, Schuler AD, Bedalov A and Simon JA: Development of pyrazolone and isoxazol-5-one cambinol analogues as sirtuin inhibitors. J Med Chem. 57:3283–3294. 2014. View Article : Google Scholar : PubMed/NCBI | |
Yang L, Liang Q, Shen K, Ma L, An N, Deng W, Fei Z and Liu J: A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells. Biomed Pharmacother. 71:70–78. 2015. View Article : Google Scholar : PubMed/NCBI | |
Eigl BJ, North S, Winquist E, Finch D, Wood L, Sridhar SS, Powers J, Good J, Sharma M, Squire JA, et al: A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. Invest New Drugs. 33:969–976. 2015. View Article : Google Scholar : PubMed/NCBI | |
Cui J, Sun W, Hao X, Wei M, Su X, Zhang Y, Su L and Liu X: EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cells. Cancer Cell Int. 15:42015. View Article : Google Scholar : PubMed/NCBI | |
Fu L, Yan FX, An XR and Hou J: Effects of the histone methyltransferase inhibitor UNC0638 on histone H3K9 dimethylation of cultured ovine somatic cells and development of resulting early cloned embryos. Reprod Domest Anim. 49:e21–e25. 2014. View Article : Google Scholar : PubMed/NCBI | |
Tiffen JC, Gunatilake D, Gallagher SJ, Gowrishankar K, Heinemann A, Cullinane C, Dutton-Regester K, Pupo GM, Strbenac D, Yang JY, et al: Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes. Oncotarget. 6:27023–27036. 2015. View Article : Google Scholar : PubMed/NCBI | |
Horiuchi KY, Eason MM, Ferry JJ, Planck JL, Walsh CP, Smith RF, Howitz KT and Ma H: Assay development for histone methyltransferases. Assay Drug Dev Technol. 11:227–236. 2013. View Article : Google Scholar : PubMed/NCBI | |
Maes T, Mascaró C, Ortega A, Lunardi S, Ciceri F, Somervaille TC and Buesa C: KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease. Epigenomics. 7:609–626. 2015. View Article : Google Scholar : PubMed/NCBI | |
Qian S, Wang Y, Ma H and Zhang L: Expansion and functional divergence of Jumonji C-containing histone demethylases: Significance of duplications in ancestral angiosperms and vertebrates. Plant Physiol. 168:1321–1337. 2015. View Article : Google Scholar : PubMed/NCBI | |
Verrotti A, Carelli A, di Genova L and Striano P: Epilepsy and chromosome 18 abnormalities: A review. Seizure. 32:78–83. 2015. View Article : Google Scholar : PubMed/NCBI | |
Cinatl J Jr, Cinatl J, Scholz M, Driever PH, Henrich D, Kabickova H, Vogel JU, Doerr HW and Kornhuber B: Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs. 7:766–773. 1996. View Article : Google Scholar : PubMed/NCBI | |
Woodworth AM and Holloway AF: The role of epigenetic regulation in transcriptional memory in the immune system. Adv Protein Chem Struct Biol. 106:43–69. 2017. View Article : Google Scholar : PubMed/NCBI | |
Iwahashi S, Utsunomiya T, Imura S, Morine Y, Ikemoto T, Arakawa Y, Saito Y, Ishikawa D and Shimada M: Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: Clinical study phases I/II. Anticancer Res. 34:5187–5191. 2014.PubMed/NCBI | |
Sugimoto K, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T and Iwahashi S: Valproic acid enhances the anti-tumor effect of pegylated interferon-α towards pancreatic cancer cell lines. Anticancer Res. 34:3403–3409. 2014.PubMed/NCBI | |
Bastos LF and Coelho MM: Drug repositioning: Playing dirty to kill pain. CNS Drugs. 28:45–61. 2014. View Article : Google Scholar : PubMed/NCBI | |
Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, et al: Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 487:482–485. 2012. View Article : Google Scholar : PubMed/NCBI | |
Di Costanzo A, Del Gaudio N, Migliaccio A and Altucci L: Epigenetic drugs against cancer: An evolving landscape. Arch Toxicol. 88:1651–1668. 2014. View Article : Google Scholar : PubMed/NCBI | |
Mummaneni P and Shord SS: Epigenetics and oncology. Pharmacotherapy. 34:495–505. 2014. View Article : Google Scholar : PubMed/NCBI | |
Glaser KB: HDAC inhibitors: Clinical update and mechanism-based potential. Biochem Pharmacol. 74:659–671. 2007. View Article : Google Scholar : PubMed/NCBI | |
Li X, Mei Q, Nie J, Fu X and Han W: Decitabine: A promising epi-immunotherapeutic agent in solid tumors. Expert Rev Clin Immunol. 11:363–375. 2015. View Article : Google Scholar : PubMed/NCBI | |
Garrido-Laguna I, McGregor KA, Wade M, Weis J, Gilcrease W, Burr L, Soldi R, Jakubowski L, Davidson C, Morrell G, et al: A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Invest New Drugs. 31:1257–1264. 2013. View Article : Google Scholar : PubMed/NCBI | |
Zhou C, Ji J, Shi M, Yang L, Yu Y, Liu B, Zhu Z and Zhang J: Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin–induced Src activation in gastric cancer cells. Mol Med Rep. 10:2729–2735. 2014. View Article : Google Scholar : PubMed/NCBI | |
Karthik S, Sankar R, Varunkumar K and Ravikumar V: Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells. Biomed Pharmacother. 68:327–334. 2014. View Article : Google Scholar : PubMed/NCBI | |
Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stütz AM, Wang X, Gallo M, Garzia L, Zayne K, et al: Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature. 506:445–450. 2014. View Article : Google Scholar : PubMed/NCBI | |
Tabatabaeifar S, Kruse TA, Thomassen M, Larsen MJ and Sørensen JA: Use of next generation sequencing in head and neck squamous cell carcinomas: A review. Oral Oncol. 50:1035–1040. 2014. View Article : Google Scholar : PubMed/NCBI |